Grade 1 Follicular Lymphoma

Observed

→ investigated in trials for

Fludarabinesmall molecule

26 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cyclophosphamidesmall molecule

19 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Lenalidomidesmall_molecule

15 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Bortezomibsmall molecule

11 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Etoposidesmall molecule

10 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Ibrutinibsmall molecule

10 trials (4 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Filgrastimother

9 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Obinutuzumabmonoclonal antibody

9 trials (5 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Vorinostatsmall molecule

8 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Bendamustinesmall molecule

7 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Busulfansmall molecule

7 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Dexamethasonesmall molecule

5 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Melphalansmall molecule

5 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Tanespimycinsmall molecule

5 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

Grade 1 Follicular Lymphoma studied in …STUDIED_INderived10 of 186show all (up to 200)
→ studied in	NCT02992522Phase 1 · active not recruiting Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 186 trials mapped (23 active)	—	—	Grade 1 Follicular Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03015896Phase 1/Phase 2 · completed Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma · condition mapped CURATED_BROADER · 186 trials mapped (23 active)	—	—	Grade 1 Follicular Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06453044Phase 2 · recruiting Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma · condition mapped CURATED_BROADER · 186 trials mapped (23 active)	—	—	Grade 1 Follicular Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07731789Phase 2 · not yet recruiting Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma · condition mapped ONTOLOGY_EXACT · 186 trials mapped (23 active)	—	—	Grade 1 Follicular Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT01318317Phase 1/Phase 2 · active not recruiting Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 186 trials mapped (23 active)	—	—	Grade 1 Follicular Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT01849263Phase 2 · active not recruiting Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma · condition mapped CURATED_BROADER · 186 trials mapped (23 active)	—	—	Grade 1 Follicular Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06442475Phase 2 · recruiting Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 186 trials mapped (23 active)	—	—	Grade 1 Follicular Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03150329Phase 1 · active not recruiting Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL. · condition mapped CURATED_BROADER · 186 trials mapped (23 active)	—	—	Grade 1 Follicular Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03198026Phase 2 · active not recruiting Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas · condition mapped ONTOLOGY_EXACT · 186 trials mapped (23 active)	—	—	Grade 1 Follicular Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT01479842Phase 1 · active not recruiting Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma · condition mapped CURATED_BROADER · 186 trials mapped (23 active)	—	—	Grade 1 Follicular Lymphoma	1	Observed	clinicaltrials	graph →

Grade 1 Follicular Lymphoma studied in …STUDIED_INderived10 of 186show all (up to 200)

→ studied in

NCT02992522Phase 1 · active not recruiting

Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 186 trials mapped (23 active)

—

Observed

→ studied in

NCT03015896Phase 1/Phase 2 · completed

Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma · condition mapped CURATED_BROADER · 186 trials mapped (23 active)

—

Observed

→ studied in

NCT06453044Phase 2 · recruiting

Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma · condition mapped CURATED_BROADER · 186 trials mapped (23 active)

—

Observed

→ studied in

NCT07731789Phase 2 · not yet recruiting

Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma · condition mapped ONTOLOGY_EXACT · 186 trials mapped (23 active)

—

Observed

→ studied in

NCT01318317Phase 1/Phase 2 · active not recruiting

Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 186 trials mapped (23 active)

—

Observed

→ studied in

NCT01849263Phase 2 · active not recruiting

Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma · condition mapped CURATED_BROADER · 186 trials mapped (23 active)

—

Observed

→ studied in

NCT06442475Phase 2 · recruiting

Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 186 trials mapped (23 active)

—

Observed

→ studied in

NCT03150329Phase 1 · active not recruiting

Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL. · condition mapped CURATED_BROADER · 186 trials mapped (23 active)

—

Observed

→ studied in

NCT03198026Phase 2 · active not recruiting

Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas · condition mapped ONTOLOGY_EXACT · 186 trials mapped (23 active)

—

Observed

→ studied in

NCT01479842Phase 1 · active not recruiting

Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma · condition mapped CURATED_BROADER · 186 trials mapped (23 active)

—

Observed